Physicians and Other Healthcare Providers Can Now Request Patient Testing for Propensity to Diabetic Kidney Disease

It is widely recognized that patients with diabetes are likely to have varying susceptibility to the development of debilitating diabetes-related kidney disease. A significant problem that you and patients with diabetes face is the 5-20 year "silent phase" after onset of diabetes when you cannot differentiate a high susceptibility sub-group from a relatively protected cohort when both have no apparent clinical symptoms or signs.

Until now, we have not been able to predict which patients are most likely to develop these complications, and therefore we have been unable to tailor medical treatment to an individual patient’s needs.  Also, by the time symptoms are apparent, it is often too late to change the outcome, even with more aggressive treatment. Your patients who are unaware of their risks are often complacent and unresponsive when knowledge of this risk would prompt more attentive behavior that, with your help, could dramatically change their outcome. Our overarching objective is to fundamentally improve your ability to care for your patients with diabetes by providing diagnostic tests that will predict individual propensity to diabetic complications. These unique tests fill an essential, unmet need, providing you and your patients with the information necessary to make proactive, individualized decisions about diabetes care.

You can request testing for your patients with Type 1 and Type 2 Diabetes

PreventAGE Health Care has full CLIA certification, and offers precision blood testing for specific Advanced Glycation End-Products (AGEs) that can predict risk of diabetic kidney disease for patients with Type 1 or Type 2 diabetes early, prior to significant GFR decline, or onset of albuminuria.  Based on proprietary databases, we will provide you and your patients with an individualized Compass™ (Complications Propensity Assessment) Type 1 (Compass T1) or Type 2 (Compass T2) report that will indicate the risk of future kidney disease progression. These highly accurate risk scores are based on our proprietary data generated by the landmark JDRF (Type 1) and NIDDK (Type 2) sponsored kidney outcome studies.  Risk scores are derived from levels of specific AGEs for Type 1 diabetes, and from the combination of these same AGEs and traditional kidney disease risk factors for Type 2 diabetes. This information is intended to be used by you and your patients with diabetes to predict risk, personalize treatments, and above all to improve outcomes.

Similar testing for cardiovascular disease will be available soon.

 

 

 

For Laboratory License click here